Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 8, Issue 3, Pages 235-253Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2792
Keywords
-
Funding
- NIDCR NIH HHS [R01-DE13686, R01 DE013686] Funding Source: Medline
- NIGMS NIH HHS [T32 GM066704, T32-GM066704-05] Funding Source: Medline
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066704] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family. This Review discusses traditional applications of recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphataemic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
